04:42 PM EDT, 06/25/2024 (MT Newswires) -- Merck's ( MRK ) animal-health unit said late Tuesday its Nobivac NXT Canine Flu H3N2 vaccine won approval from the US Department of Agriculture.

The vaccine, which protects against the most prevalent dog flu virus circulating in the US, is expected to be available at veterinary clinics and hospitals late this summer, the company said.

The product uses RNA-particle technology to protect dogs against the disease, Merck Animal Health said. It's indicated for dogs eight weeks of age or older against canine influenza H3N2.

Price: 132.66, Change: -0.26, Percent Change: -0.20